Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of Cagrilintide and Survodutide — mechanism, dosing, side effects, legal status, and pricing.
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Survodutide is a dual GLP-1 / glucagon receptor agonist co-developed by Boehringer Ingelheim and Zealand Pharma. NOT FDA-approved; received FDA Breakthrough Therapy Designation in 2024 for non-cirrhotic MASH with moderate/advanced fibrosis. Phase 3 ongoing (SYNCHRONIZE in obesity/T2DM; LIVERAGE and LIVERAGE-Cirrhosis in MASH).
Cagrilintide
Survodutide
Category
Legal Status
Mechanism
Dose Range
Route
Frequency
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
Cagrilintide
Survodutide
COA corpus from Disclosed Labs — independently tested batches only.
Cagrilintide
79
COAs
99.7%
Avg purity
13
Labs
Survodutide
10
COAs
99.7%
Avg purity
4
Labs
A Phase 2 dose-finding trial of cagrilintide monotherapy demonstrated dose-dependent weight loss of up to 10.8% over 26 weeks versus 3.0% for placebo (Lau et al., The Lancet, 2021). Novo Nordisk pivoted development to the CagriSema co-formulation with semaglutide 2.4 mg. The Phase 3 REDEFINE 1 trial (n=3,417, 68 weeks) in obesity reported ~22.7% mean body weight reduction on the treatment-policy estimand, with 91.9% achieving ≥5% weight loss versus 31.5% for placebo. Novo Nordisk submitted a CagriSema NDA to the FDA in December 2025; the application is under review in 2026. Cagrilintide is not FDA-approved as a standalone therapy, and CagriSema is not yet approved as of April 2026.
Key references
Phase 2 MASH trial (Sanyal et al., NEJM 2024; 48 weeks, F1–F3 fibrosis): MASH resolution without worsening of fibrosis in 47% (2.4 mg), 62% (4.8 mg), and 43% (6.0 mg) vs 14% placebo. Phase 2 obesity trial reported ~19% weight loss at 46 weeks at the highest dose. Dose-dependent heart-rate elevation has been observed.
Cagrilintide and Survodutide are both in the Metabolic category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Dosing Notes
Side Effects
Contraindications
Lab Testing
Disclosed Labs